速递｜专利仅剩20天！34亿+重磅减重药降价50%，国产大军群狼环伺

Core Viewpoint - The article discusses the impending patent expiration of Semaglutide (GLP-1 receptor agonist) in March 2026, which will lead to increased competition from generic drug manufacturers and a potential price war in the weight loss medication market [5][6]. Group 1: Patent Expiration and Market Impact - Semaglutide has gained significant market share in the weight loss drug sector due to its effectiveness in lowering blood sugar and aiding weight loss, with sales exceeding 3.4 billion yuan in the first three quarters of 2025 [8]. - The patent expiration will allow at least ten domestic pharmaceutical companies, including Jiuyuan Gene and Lizhu Group, to launch their own generic versions of Semaglutide, intensifying market competition [6][10]. - Jiuyuan Gene's biosimilar, Jikeqin®, has shown comparable efficacy and safety to the original drug in clinical trials, indicating a strong entry into the market [6]. Group 2: Competitive Landscape - Novo Nordisk, the original manufacturer of Semaglutide, is facing competition not only from generics but also from Eli Lilly's upcoming oral GLP-1RA, Orforglipron, which has demonstrated superior efficacy in clinical trials [9]. - Orforglipron is expected to achieve sales of $11.8 billion by 2032, highlighting the competitive pressure on Semaglutide as new entrants emerge [9]. - In response to competition, Novo Nordisk has announced significant price reductions for Semaglutide in the U.S. and domestic markets, with price cuts ranging from 35% to 50% [8]. Group 3: Future Outlook and Strategies - The article emphasizes the need for original drug manufacturers to accelerate new drug development or consider mergers and acquisitions to fill revenue gaps as generics flood the market [10][11]. - Domestic companies are innovating in drug formulations, with some introducing long-acting versions and even nasal spray formulations of Semaglutide to differentiate themselves [10]. - The market dynamics are shifting towards efficiency and cost-effectiveness, with companies needing to adapt to consumer preferences for quick and affordable access to medications [11].